There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PLAU


Brief Information

Name:Urokinase plasminogen activator
Target Synonym:PLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC:,EC 3.4.21,U-Plasminogen Activator,EC
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
PLU-H5228 Human Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
PLU-H5229 Human Human PLAU / uPA Protein, His Tag

Part of Bioactivity data

Human PLAU, His TagHuman PLAU, His Tag (Cat. No. PLU-H5229) ELISA bioactivity

Immobilized Human PLAU, His Tag (Cat. No. PLU-H5229) at 5 μg/mL (100 μL/well) can bind Biotinylated Human uPAR, His,Avitag with a linear range of 0.3-2 ng/mL (QC tested).

Synonym Name



Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Urokinase biosimilar (Bharat Serums & Vaccines) U-FRAG Approved Bharat Serums And Vaccines Pulmonary Embolism Details
Nasaruplase GE-0943 Approved Mitsubishi Pharma Corp Tomieze, Thrombolyse Japan Myocardial Infarction; Venous Thrombosis Mitsubishi Pharma Corp 1992-01-01 Myocardial Infarction; Venous Thrombosis Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Gallium-68 NOTA AE105 (Curasight) CS-001; 68Ga-NOTA-AE105 Phase 2 Clinical Curasight Head and Neck Neoplasms; Glioblastoma; Neuroendocrine Tumors; Mesothelioma; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Oropharyngeal Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung Details
tPA/HisproUK (Thrombolytic Science) TS-01 Phase 2 Clinical Thrombolytic Science Stroke Details
Upamostat Hydrogen Sulphate LH-011; WX-671 Phase 3 Clinical Wilex Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Breast Neoplasms; Colorectal Neoplasms Details
Recombinant human annexin 5 protein (Yabao Pharmaceuticals) SY-005 Phase 2 Clinical Lawson Health Research Institute, Yabao Pharmaceutical Group Co Ltd Sepsis Details
Angstrom6 A6 Phase 2 Clinical Angstrom Ovarian Neoplasms; Peritoneal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.